The DNA Damage Pathway Regulates Innate Immune System Ligands of the NKG2D Receptor
Affiliations
Some stimulatory receptors of the innate immune system, such as the NKG2D receptor (also called KLRK1) expressed by natural killer cells and activated CD8(+)T cells, recognize self-molecules that are upregulated in diseased cells by poorly understood mechanisms. Here we show that mouse and human NKG2D ligands are upregulated in non-tumour cell lines by genotoxic stress and stalled DNA replication, conditions known to activate a major DNA damage checkpoint pathway initiated by ATM (ataxia telangiectasia, mutated) or ATR (ATM- and Rad3-related) protein kinases. Ligand upregulation was prevented by pharmacological or genetic inhibition of ATR, ATM or Chk1 (a downstream transducer kinase in the pathway). Furthermore, constitutive ligand expression by a tumour cell line was inhibited by targeting short interfering RNA to ATM, suggesting that ligand expression in established tumour cells, which often harbour genomic irregularities, may be due to chronic activation of the DNA damage response pathway. Thus, the DNA damage response, previously shown to arrest the cell cycle and enhance DNA repair functions, or to trigger apoptosis, may also participate in alerting the immune system to the presence of potentially dangerous cells.
Chou S, Kuo C, Ko H, Huang P, Liu C, Wang L Exp Ther Med. 2025; 29(4):72.
PMID: 39991723 PMC: 11843192. DOI: 10.3892/etm.2025.12822.
Qi Z, Li Q, Yang S, Fu C, Hu B Biomedicines. 2025; 13(1).
PMID: 39857814 PMC: 11761251. DOI: 10.3390/biomedicines13010231.
Genomic instability as a driver and suppressor of anti-tumor immunity.
Requesens M, Foijer F, Nijman H, de Bruyn M Front Immunol. 2024; 15:1462496.
PMID: 39544936 PMC: 11562473. DOI: 10.3389/fimmu.2024.1462496.
CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside.
Zhu X, Xue J, Jiang H, Xue D Mol Cancer. 2024; 23(1):237.
PMID: 39443938 PMC: 11515662. DOI: 10.1186/s12943-024-02151-3.
Immunological signatures from irradiated cancer-associated fibroblasts.
Berzaghi R, Gundersen K, Dille Pedersen B, Utne A, Yang N, Hellevik T Front Immunol. 2024; 15:1433237.
PMID: 39308864 PMC: 11412886. DOI: 10.3389/fimmu.2024.1433237.